Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Inhibition of Immune Cell Subsets Is Differentially Affected By Dasatinib Dosage in Patients with Chronic Phase CML

Patrick Harrington, MRCP, FRCPath, Richard Dillon, MA, PhD MRCP, FRCPath, Deepti H. Radia, MRCPI, FRCPath, Donal P. McLornan, MRCP, PhD FRCPath, Philippe Rousselot, MDPhD, Katayoun Rezvani, MD PhD, Shahram Kordasti, MD PhD, Claire Harrison, DM, FRCP, FRCPath, Hugues de Lavallade, MD PhD

Blood (2020) 136 (Supplement 1): 51–53.

https://doi.org/10.1182/blood-2020-139501

Published: 2020

Journal Articles

Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML

Jorge E. Cortes, MD, Jane Apperley, FRCP, FRCPath, MB, Andreas Hochhaus, MD, Michael J. Mauro, MD, Philippe Rousselot, MDPhD, Tomasz Sacha, MDPhD, Moshe Talpaz, MD, Charles Chuah, MD, Jeffrey H. Lipton, MD PhD, Michael W. Deininger, MD PhD, Charles A. Schiffer, MD, Lori J. Maness, MD, James K. McCloskey, MD, Valentín García Gutiérrez, MD PhD, Hugues de Lavallade, MD PhD, Gabriel Etienne, MD PhD, Vickie Lu, PhD, Shouryadeep Srivastava, MBBS, PhD, Gianantonio Rosti, MD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-135883

Published: 2020

Journal Articles

Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-139847

Published: 2020

Journal Articles

Prospective Evaluation of ABL Kinase Domain Mutational Analysis By Next-Generation-Sequencing in Newly Diagnosed CP CML Patients Undergoing First-Line Treatment with Nilotinib Alone or Nilotinib + Pegylated Interferon-α2a in a Prospective Phase III Trial

Hugues de Lavallade, MD PhD, Sophie Jackson, BSc, Aytug Kizilors, PhD, Gabriel Etienne, MD PhD, Francoise Huguet, MD, Agnes Guerci-Bresler, MD PhD, Delphine Rea, MD, Claudine Chollet, MSc, Stephane Morisset, BioStat, Fanny Robbesyn, BSc, Francois-Xavier Mahon, MD PhD, Stephanie Dulucq, PharmD, PhD, Franck E Nicolini, MD PhD

Blood (2019) 134 (Supplement_1): 664.

https://doi.org/10.1182/blood-2019-125108

Published: 2019

Journal Articles

Post-Transplant Flow Cytometry MRD Predicts Relapse in a Real World AML Cohort

Henry Wood, MBBS, Katy Sanchez, BSc, MSc, Victoria Potter, MBBS, BSc, FRACP, FRCPA, Austin Kulasekararaj, MD MRCP, FRCPath, Hugues de Lavallade, MD PhD, Deborah Yallop, MBBS, FRCP, FRCPath, PhD, Shireen Kassam, MBBS, FRCPath, PhD, Robin M. Ireland, MBBS, FRCP, FRCPath, Antonio Pagliuca, MBBS, MA, FRCP, FRCPath, Ghulam J. Mufti, MBBS, FRCP, FRCPath, DM, Alan Dunlop, BSc, MSc

Blood (2019) 134 (Supplement_1): 4566.

https://doi.org/10.1182/blood-2019-131711

Published: 2019

Journal Articles

Impact of Finding of Low Level Kinase Domain Mutations Using Ultra Deep Next Generation Sequencing in Patients with Chronic Phase CML

Aytug Kizilors, PhD, Elena Crisa, MD, Nicholas Lea, PhD, Steven Best, PhD, Mian Syed, PhD, Robin M. Ireland, FRCP, FRCPath, Maadh Aldouri, FRCPath, Christopher Pocock, Timothy Corbett, FRCP, FRCPath, Emily Elizabeth Bart-Smith, MRCP,BSc, Richard Gale, FRCPath, FRCP, Clare Wykes, FRCPath, FRCP, Simon Weston-Smith, FRCP, FRCPath, Donal McLornan, MDPhD, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Ghulam J. Mufti, MD PhD, Hugues de Lavallade, MD PhD

Blood (2015) 126 (23): 347.

https://doi.org/10.1182/blood.V126.23.347.347

Published: 2015

Journal Articles

Increased Mortality in Patients with Autoimmune Hemolytic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation

Meng Wang, MD PhD, Wenjia Wang, PhD, Ayesha Abeywardane, MD, Malinthi Adikarama, MD, Donal McLornan, MD PhD FRCPath, Kavita Raj, MD PhD FRCPath, Hugues de Lavallade, MD PhD, Stephen Devereux, MD PhD FRCPath, Ghulam J. Mufti, DM, FRCP, FRCPath, Antonio Pagliuca, MD FRCP, FRCPath, Victoria T Potter, MD FRCPA, FRACP, Aleksandar Mijovic

Blood (2014) 124 (21): 2512.

https://doi.org/10.1182/blood.V124.21.2512.2512

Published: 2014

Journal Articles

King’s College Hospital FCC Conditioning for Severe Aplastic Anemia Induces Tolerance with Mixed T-Cell Chimerism and Extremely Low Incidence of Gvhd

Francesco Grimaldi, MD, Linda D Barber, PhD, Pilar Perez-Abellan, MSc, Rosemary Grain, Victoria T Potter, MD FRCPA, FRACP, Austin Kulasekararaj, Donal McLornan, MD PhD FRCPath, Kavita Raj, MD PhD FRCPath, Hugues de Lavallade, MD PhD, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Ghulam J. Mufti, MD PhD, Judith C Marsh, MD

Blood (2014) 124 (21): 1594.

https://doi.org/10.1182/blood.V124.21.1594.1594

Published: 2014

Journal Articles

Busulfan-Dose Escalation in Reduced Intensity Stem Cell Transplantation (RIC-HSCT) Results in Good Outcomes for Patients with MDS and AML without Increased Toxicity

Anita Sarma, MBChB, BSc, MRCP, Victoria T Potter, MD FRCPA, FRACP, Jennifer Clay, BM BS, FRACP, FRCPA, Donal McLornan, MD PhD FRCPath, Hugues de Lavallade, MD PhD, Kavita Raj, Judith C. W. Marsh, Austin Kulasekararaj, Antonio Pagliuca, MD FRCP, FRCPath, Ghulam Mufti, MD DM, FRCP, FRCPath

Blood (2014) 124 (21): 1236.

https://doi.org/10.1182/blood.V124.21.1236.1236

Published: 2014

NARROW

Inhibition of Immune Cell Subsets Is Differentially Affected By Dasatinib Dosage in Patients with Chronic Phase CML

Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML

Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib

Prospective Evaluation of ABL Kinase Domain Mutational Analysis By Next-Generation-Sequencing in Newly Diagnosed CP CML Patients Undergoing First-Line Treatment with Nilotinib Alone or Nilotinib + Pegylated Interferon-α2a in a Prospective Phase III Trial

Post-Transplant Flow Cytometry MRD Predicts Relapse in a Real World AML Cohort

Impact of Finding of Low Level Kinase Domain Mutations Using Ultra Deep Next Generation Sequencing in Patients with Chronic Phase CML

Increased Mortality in Patients with Autoimmune Hemolytic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation

King’s College Hospital FCC Conditioning for Severe Aplastic Anemia Induces Tolerance with Mixed T-Cell Chimerism and Extremely Low Incidence of Gvhd

Busulfan-Dose Escalation in Reduced Intensity Stem Cell Transplantation (RIC-HSCT) Results in Good Outcomes for Patients with MDS and AML without Increased Toxicity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only